Home › Compare › KYYWF vs ABBV
KYYWF yields 0.10% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, KYYWF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of KYYWF + ABBV for your $10,000?
Keywords Studios plc provides integrated outsourced creative and technical services to the video game industry. The company offers art creation services related to the production of graphical art assets for inclusion in the video game, including concept art creation, as well as 2D and 3D art asset production and animation. It also provides marketing services, which include game trailers, marketing art and materials, PR, and brand campaign services; and audio/voice-over services, including script translation, actor selection, and talent management through pre-production, audio direction, recording, and post-production, as well as offers music licensing or music soundtracks selling services. In addition, the company offers localization services related to translation and cultural adaptation of in-game text and audio scripts in various game platforms and genres; and localization testing services consisting of testing the linguistic correctness and cultural acceptability of computer games. Further, it provides functional testing services related to quality assurance services provided to game producers to ensure game functions. Additionally, the company provides player support services related to the live operations support, such as community management, player support, and associated services to producers of games, as well as software engineering services for developing video games. It serves game developers and publishers. The company operates in Canada, the United States, the United Kingdom, Italy, Russia, Japan, Poland, China, India, Ireland, the Philippines, Spain, France, Singapore, Australia, and internationally. Keywords Studios plc was founded in 1998 and is headquartered in Dublin, Ireland.
Full KYYWF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.